AI-generated analysis. Always verify with the original filing.
PAVmed Inc. reported a net loss of $2.5 million for the fiscal year ending December 31, 2025, as per the cash flow statement. The company's net cash used in operating activities was $5.2 million. Total assets stood at $38.8 million, with total liabilities of $16.5 million, resulting in total stockholders' equity of $22.3 million. The company's cash position increased by $353k during the year, ending at $19.6 million. Key subsidiaries include Lucid Diagnostics, focused on the EsoGuard esophageal cancer test, and Veris Health, developing a digital cancer care platform. The company's financial statements include a going concern qualification due to recurring losses and the need for additional capital.
Net Income
-$2.5M
free cash flow
-$5.2M